Back to search

Article

Targeting USP2 induces degradation of PML-RARα with or without drug-resistant mutations in acute promyelocytic leukemia

2025-05-14

Abstract excerpt

Despite the high efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in treating acute promyelocytic leukemia (APL), approximately 10-20% of patients develop drug resistance due to mutations in PML-RARα and other factors. Here, it is demonstrated that inhibiting USP2 with ML364 or silencing USP2 reduces PML-RARα protein levels in both ATRA-sensitive and -resistant APL cells, an effect reversed by...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
64628228-792a-572d-b955-63c18012f40a
DOI
10.1101/2025.05.11.653221
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting USP2 induces degradation of PML-RARα with or without drug-resistant mutations in acute promyelocytic leukemiaDOI 10.1101/2025.05.11.653221
Select a neighboring publication to make it the new centre.